Walleye Capital LLC Reduces Stock Position in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Walleye Capital LLC reduced its stake in Agios Pharmaceuticals by 28.6%, owning 150,511 shares after selling 60,227 shares during the first quarter.
• Multiple hedge funds, including Wells Fargo & Company and Hsbc Holdings PLC, significantly increased their holdings in Agios Pharmaceuticals, with Wells Fargo growing its stake by 184.9%.
• Analysts have mixed sentiments about Agios Pharmaceuticals, with Scotiabank lowering its target price from $71.00 to $65.00 while maintaining a "sector outperform" rating.

Walleye Capital LLC lessened its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 28.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 150,511 shares of the biopharmaceutical company's stock after selling 60,227 shares during the quarter. Walleye Capital LLC owned about 0.26% of Agios Pharmaceuticals worth $4,410,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. Jefferies Financial Group Inc. purchased a new position in Agios Pharmaceuticals in the 4th quarter valued at $49,290,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $9,084,000. Deutsche Bank AG lifted its stake in Agios Pharmaceuticals by 39.7% in the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Agios Pharmaceuticals by 207.6% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 386,523 shares of the biopharmaceutical company's stock worth $11,325,000 after purchasing an additional 260,845 shares in the last quarter. Finally, Casdin Capital LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $8,215,000.

Agios Pharmaceuticals Stock Down 1.2%

NASDAQ AGIO traded down $0.47 on Friday, reaching $37.71. The stock had a trading volume of 502,787 shares, compared to its average volume of 936,872. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 3.43 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58. The stock has a fifty day moving average price of $37.12 and a two-hundred day moving average price of $33.05.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 11,914 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total transaction of $452,612.86. Following the sale, the insider directly owned 61,271 shares of the company's stock, valued at $2,327,685.29. This represents a 16.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Scadden sold 1,400 shares of the company's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $40.00, for a total value of $56,000.00. Following the sale, the director directly owned 17,603 shares in the company, valued at $704,120. This represents a 7.37% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,448 shares of company stock valued at $2,026,141. 4.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on AGIO shares. Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research report on Monday, July 28th. Finally, Bank of America reduced their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.